CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia

D A Arber1, K A Jenkins, M L Slovak

  • 1Division of Pathology, City of Hope National Medical Center, Duarte, California 91010, USA.

Insights

CD79 alpha, a B lymphocyte protein, is expressed in acute myeloid leukemia (AML), particularly in acute promyelocytic leukemia (APL). This finding expands the understanding of CD79 alpha expression beyond B-lineage acute lymphoblastic leukemia.

Area of Science:

  • Hematology
  • Immunophenotyping
  • Molecular Diagnostics

Background:

  • CD79 alpha is typically a B lymphocyte-specific protein.
  • Its expression in acute myeloid leukemia (AML) requires further investigation.

Purpose of the Study:

  • To evaluate CD79 alpha antigen expression in various subtypes of AML.
  • To determine the association of CD79 alpha expression with specific AML genetic alterations, such as t(15;17).

Main Methods:

  • Studied 48 AML cases using paraffin section immunohistochemistry.
  • Classified AML subtypes according to French-American-British (FAB) criteria (M0-M5).
  • Investigated co-expression of other B-lineage antigens and the presence of t(15;17) translocation.

Main Results:

  • CD79 alpha cytoplasmic staining was observed in 11 out of 48 AML cases.
  • Notably, 90% of acute promyelocytic leukemias (APL, M3) and 5% of non-promyelocytic AMLs expressed CD79 alpha.
  • All APL cases harbored the characteristic t(15;17) translocation; CD79 alpha-positive non-APL cases lacked B-lineage markers or t(15;17).

Conclusions:

  • CD79 alpha expression in acute leukemia is not exclusive to B-lineage acute lymphoblastic leukemia.
  • CD79 alpha positivity is frequently associated with acute promyelocytic leukemia (M3) and the t(15;17) translocation.
  • This suggests a potential role for CD79 alpha as a marker in specific AML subtypes beyond B-cell malignancies.